Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
== Combination with other antidiabetic drugs == A combination therapy of insulin and other antidiabetic drugs appears to be most beneficial in people who are diabetic, who still have residual insulin secretory capacity. A combination of insulin therapy and sulfonylurea is more effective than insulin alone in treating people with type 2 diabetes after secondary failure to oral drugs, leading to better glucose profiles or decreased insulin needs.
She saw the base of the Battalion "Vostok" in Gudermes somewhere in that time frame. Chechen soldiers were preparing to go to South Ossetia. It was claimed that they were going to support the peacekeeping mission. At 3:30 am they began preparing for departure with military official reminding them not to forget their passports and military IDs. However, the article does not mention that there was any war in South Ossetia. On 10 August 2008, Moskovskij Komsomolets published a report by journalist who was in Tskhinvali on the night of 7 August. The report states, "There are 1700 peacekeepers here." According to Russian Defence Ministry official, the 1990s ceasefire agreement allowed Russia to station 500 peacekeepers in the conflict zone with 300 additional peacekeepers being reserved to be deployed during emergency. On 10 August 2008, Izvestia published a report by journalist who had been in Tskhinvali. Journalist Yuri Snegirev wrote that he had witnessed Russian military servicemen, who were not peacekeepers, in Tskhinvali bomb shelter on 8 August 2008. On 12 August 2008, Komsomolskaya Pravda reported that in South Ossetia, several soldiers were wounded and one was killed, who were from Tatarstan. Five days before he was killed in South Ossetia, Evgeny Parfenov warned his parents not to call him because it would be hard to reach him by phone. Lieutenant Aleksandr Popov was participating in the exercises on the height near Tskhinvali when his group was requested by the intelligence to reinforce them.
University of Cincinnati Health (branded as UC Health) is the healthcare system of the University of Cincinnati, in Cincinnati, Ohio. It trains health care professionals and provides research and patient care. The system is affiliated with the university via the University of Cincinnati Academic Health Center (AHC). Most of the system's facilities are spread among two major campuses in the Cincinnati metropolitan area: the Clifton campus, home to the flagship University of Cincinnati Medical Center, and the West Chester campus, home to West Chester Hospital. There are also locations in Florence, Kentucky, and other Ohio communities.
== See also == List of antidepressants Serotonin modulator and stimulator (SMS) Noradrenergic and specific serotonergic antidepressant (NaSSA) Norepinephrine-dopamine disinhibitor (NDDI) Selective serotonin reuptake inhibitor (SSRI) DSP-6745
Lineage, Inc. (formerly Lineage Logistics) is the world's largest temperature-controlled warehouse real estate investment trust (REIT), owned by Bay Grove, LLC. Entering international markets in 2017, Lineage grew into the world's largest refrigerated warehousing company with a capacity exceeding 3 billion cubic feet and acquiring more than 100 companies through the end of 2023. Lineage operates over 450 facilities across 18 countries, with approximately 26,000 team members globally in North America, Europe, and Asia Pacific.
Sources: en.wikipedia.org
=== Solar cooking === Solar cooking provides a clean and safe alternative to campfire. Using solar cookers is easy and inexpensive since they do not require fuel to work. Most solar cookers also provide the minimum required temperature during cloudy days to prepare food. Despite many advantages that solar cooking provides it is unusable during the nighttime and it will not provide heat and protection against wild animals like a campfire does.
== Internal angle bisectors and incenter == The internal angle bisectors are segments in the interior of the triangle reaching from one vertex to the opposite side and bisecting the vertex angle into two equal angles. The angle bisectors ta etc. satisfy
Harper Stern (Myha'la) is a new graduate on Pierpoint’s Cross-Product Sales (CPS) desk and one of the series’ protagonists. Brilliant, ruthless, and intensely ambitious, Harper routinely lies and manipulates to get ahead. Raised in Binghamton, New York by an abusive, domineering mother alongside her twin brother John-Daniel, she never graduated from college after suffering a panic attack during her final exams and conceals this to keep her job. She moves to London to escape her past and gravitates toward Eric Tao as a mentor who validates her drive. In series 1, Harper forges college transcripts for HR, moves into Yasmin’s flat, and forms a close but fragile friendship with her. At work, she is torn between Daria, who insists on professionalism and limits, and Eric, whose aggression mirrors her own ambition; Eric admits he knows she never graduated but protects her. Harper’s early client experiences are damaging: hedge fund manager Nicole Craig sexually assaults her, and she fails to win back major client Felim Bichan, prompting Eric to trap and berate her in a conference room. Daria urges Harper to report Eric, leading to his firing. On RIF day, Harper retracts the complaint in exchange for Eric’s reinstatement and Daria’s dismissal, believing only Eric nurtures her potential. The decision isolates her and fractures her friendship with Yasmin. In series 2, Harper remains estranged from Yasmin, and has had a casual sexual relationship with Robert.
== Installations == NNPC has sole responsibility for upstream and downstream developments. In 1988, the corporation was commercialised into 11 strategic business units, covering the entire spectrum of oil industry operations: exploration and production, gas development, refining, distribution, petrochemicals, engineering, and commercial investments.
Sources: en.wikipedia.org
Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
Each nucleotide in RNA contains a ribose sugar, with carbons numbered 1' through 5'. A base is attached to the 1' position, in general, adenine (A), cytosine (C), guanine (G), or uracil (U). Adenine and guanine are purines, and cytosine and uracil are pyrimidines. A phosphate group is attached to the 3' position of one ribose and the 5' position of the next. The phosphate groups have a negative charge each, making RNA a charged molecule (polyanion). The bases form standard hydrogen bonds between cytosine and guanine and between adenine and uracil, while guanine and uracil can pair through a non-canonical G–U wobble base pair. However, other interactions are possible, such as a group of adenine bases binding to each other in a bulge, or the GNRA tetraloop that has a guanine–adenine base-pair.
Giochi per il mio computer called the first episode professional product and an extremely compelling horror adventure. PCZeta said They Hunger has masterful use of lighting, creepy sound effects and ingenious level design. PC Player said They Hunger is the most acclaimed single-player Half-Life mod among the fan community. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "They Hunger is the best horror-themed first-person shooter since the original Blood." Planet Half-Life wrote about the first episode in 2000: "In short, the dark atmosphere is there, the weapon balance is right on, and the immersion is near-total." In 2006, they wrote: "Its sweet blend of ambience, satisfyingly intense close-quarters zombie combat (or SICQZC for short), and slick manner of horror panache make it a must-download." MegaGame noted the second episode as an excellent sequel to a remarkable game. .NetGamer called the map design and gameplay of They Hunger 2 spectacular and said it's a must-have for every Half-Life fan. GameSpot noted They Hunger 2 as Manke's current magnum opus. Level liked the second episode more than the first one. They said it's longer and more visually appealing. The levels were noted as very well crafted. Planet Half-Life said the second episode has "a tangibly different feel" and more emphasis on gunplay.
Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market. Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 μM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
=== Korean === In South Korea, soy sauces or ganjang (간장, "seasoning sauce") can be roughly split into two categories: hansik ganjang ('Korean-style soy sauce') and gaeryang ganjang ('modernized soy sauce'). The term ganjang can also refer to non-soy-based salty condiments, such as eo-ganjang fish sauce.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.